J. ter Steeg

Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors

J. Verweij, A. V. van Oosterom, A. Sparreboom, 2005, Clinical Cancer Research.

Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors.

J. Verweij, A. Sparreboom, M. D. de Jonge, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours.

J. Verweij, C. Lamers, M. D. de Jonge, 2009, European Journal of Cancer.

Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.

J. Verweij, A. V. van Oosterom, A. Sparreboom, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.